Ri­bon Ther­a­peu­tics is look­ing to break the mold for PARP in­hibitors and has a slate of Big Phar­ma back­ers on board

Ri­bon Ther­a­peu­tics broke three years of ra­dio si­lence back in ear­ly 2019 to spread the word of its $65 mil­lion Se­ries B round. Now, two and a half years lat­er, the com­pa­ny’s lead PARP in­hibitor has in­vestors reach­ing a lit­tle deep­er in­to their pock­ets.

CEO Vic­to­ria Ri­chon un­veiled a $65 mil­lion Se­ries B1 round on Wednes­day, which she de­scribed as an ex­ten­sion of the B round closed at the end of 2018. The lat­est round, led by Deer­field Man­age­ment and US Ven­ture Part­ners, brings the Cam­bridge, MA-based biotech’s to­tal raise up to about $175 mil­lion. A slate of Big Phar­ma play­ers al­so chipped in, in­clud­ing Ab­b­Vie Ven­tures, Bris­tol My­ers Squibb, John­son & John­son In­no­va­tion, Take­da Ven­tures and the No­var­tis Ven­ture Fund.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER